Clinical Trials

Several clinical trials evaluate streptavidin across diagnostic and targeted therapeutic settings, encompassing Phase I interventional and observational studies sponsored by academic institutions such as the University of Minnesota, the University of Copenhagen, and the Fred Hutchinson Cancer Center. These studies—with recruitment statuses including completed, actively recruiting, and terminated—investigate biotin interference in diagnostic blood tests for thoracic and parathyroid disorders. Additionally, research targets hematologic malignancies, including B-cell non-Hodgkin lymphomas, acute leukemias, and myelodysplastic syndromes, using pretargeted radioimmunotherapy strategies.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07302880 RECRUITING
Blood Sample; Interference With Routine Analyical Tests; Biotin Ingestion
University of Copenhagen
2026-03-17
NCT02483000 TERMINATED
Burkitt Lymphoma; CD20-Positive Neoplastic Cells Present; Diffuse Large B-Cell Lymphoma; Indolent Non-Hodgkin Lymphoma; Mantle Cell Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory Mature B-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
2017-02-01 PHASE1
NCT03034707 COMPLETED
Thoracic Diseases; Parathyroid Diseases
University of Minnesota
2016-04
NCT00988715 COMPLETED
Chronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Cytopenia With Multilineage Dysplasia; Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts; Secondary Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
2010-04-21 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-05-06)

Check the Streptavidin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Streptavidin binds noncovalently to biotin with exceptionally high affinity, forming an extraordinarily stable protein-ligand complex that sequesters biotinylated molecules and blocks their subsequent biological or chemical interactions. This targeted molecular capturing mechanism underpins pretargeted radioimmunotherapy strategies for hematologic malignancies such as B-cell non-Hodgkin lymphomas and acute leukemias, while also accounting for biotin-induced interference in clinical diagnostic laboratory assays.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.